- Bob Evans restaurant in Cape Girardeau among chain's 21 closings (04/26/16)9
- Cape student sues, accuses school officials of slamming her to ground multiple times (04/28/16)40
- Two hurt in motorcycle wreck on Interstate 55 (04/25/16)1
- Ray's of Kelso, Plaza by Ray's to change ownership; Fonn to buy enterprise (04/20/16)3
- Missouri House votes to allow concealed weapons without permits (04/28/16)6
- Law firm requests information about Cape's traffic cameras (04/25/16)2
- Tanker truck catches fire near Oak Ridge (04/24/16)7
- Local lawmakers split over failed medical marijuana bill; voters may have a say (04/26/16)19
- Local company makes eco-friendly kitty litter that cuts cat-box smell (04/25/16)
Treatment may help body sprout blood vessels near heart, in leg
LONDON -- Medication that prompts the growth of new blood vessels may one day help the body produce its own bypasses around clogged heart or leg arteries, a new study suggests.
Researchers have been experimenting with substances that stimulate blood vessel growth for nearly a decade, but a landmark study published last week is the first demonstration such substances can make patients better.
The research doesn't prove people with painfully blocked leg arteries grew new vessels, but experts say their endurance in treadmill tests was a strong indication of a beneficial effect.
"This is hopeful, but it needs further work," said Ira Herman, a professor of physiology at Tufts University who researches the growth of blood vessels, a process called angiogenesis. "While they've done blood flow measurements, that doesn't necessarily convince me that angiogenesis accounts for that improved blood flow."
Experts believe the body probably makes its own bypass blood vessels to get around blocked vessels and suspect that this rescue process does not work well in those people who have heart attacks or major blockages that need surgery.
The growth of new blood vessels is stimulated by a protein called fibroblast growth factor, or FGF-2. The researchers used a genetically engineered copy of the protein in the study.
One concern is the treatment might foster unwanted, or disease-related, blood vessel growth, perhaps causing cancer to progress.
The study, published in The Lancet medical journal, involved 174 patients with clogged leg arteries, a condition called peripheral artery disease. All the patients had intermittent cramp-like pain in their calves, a feature that doctors call claudication.
After taking a treadmill walking test, the patients were divided into three groups. One group got an injection of the protein into the main leg artery on day one and another shot of the drug a month later. The second group got the injection on day one and a dummy injection a month later, while the comparison group got fake injections both times.
Three months after the first injection, those who got the fake injection lasted 0.6 minutes longer on the treadmill than they did during the initial test, while those who got the drug on the first day stayed on the machine 1.77 minutes longer than they had on the first day. Those who got a second dose of the drug did no better than those who only got one dose.
Dr. Valentin Fuster, director of the Cardiovascular Institute at Mount Sinai Medical School in New York, said he did not think the impact on the patients was great.
"It didn't make a difference to the onset of claudication," noted Fuster, who was not connected with the study.